What Hemab does

Hemab is a clinical-stage biotechnology company developing prophylactic antibody therapies for underserved inherited bleeding and thrombotic disorders, including Glanzmann thrombasthenia, Von Willebrand Disease, and congenital Factor VII deficiency. The company is dual-headquartered in Cambridge, Massachusetts (US principal office) and Frederiksberg/Copenhagen, Denmark (research and CMC hub), was founded in 2021, and completed its upsized initial public offering on the Nasdaq Global Select Market in May 2026 under the ticker COAG, raising approximately $301.5 million in gross proceeds (~$346.7 million with overallotment) at an $18.00 offer price and reaching a ~$1.4 billion first-day market capitalization.

Hemab's pipeline is anchored by two wholly owned clinical-stage product candidates built on a modality-agnostic antibody platform that engineers bispecific and monovalent antibodies to protect endogenous coagulation proteins, drive them to hemostatic levels, and direct them to activated platelets at sites of injury. The lead asset, sutacimig (HMB-001), is a bispecific antibody that accumulates and targets endogenous FVIIa to activated platelets, currently in a fully enrolled Phase 1/2 study (with long-term extension ongoing) for Glanzmann thrombasthenia and a Phase 2 study in congenital Factor VII deficiency, supported by positive complete Phase 2 data presented at ASH 2025 and a planned pivotal Phase 3 initiation in H2 2026. The second asset, HMB-002, is a monovalent antibody that elevates circulating VWF and FVIII levels for Von Willebrand Disease, currently in the Phase 1/2 VELORA Pioneer first-in-human study and supported by the VELORA Discover natural history screening study; clinical pharmacology was published in Blood Advances in January 2026.

Hemab is pre-revenue and has no commercially approved products or pricing; its near-term revenue mechanics are limited to investigational clinical-trial supply, Medical Affairs and Patient Advocacy engagement with hematologists, hemophilia treatment centers, and rare-bleeding-disorder communities, and capital markets activity. The company is funded through a $55M Series A (2021), $135M Series B (2023), $157M Series C (2025), and the 2026 Nasdaq IPO, with approximately $460M in pro-forma cash to fund its 'Hemab 2x3 by 2030' plan of two commercial launches and six major clinical milestones by 2030. Customer segments are defined by indication (Glanzmann, VWD, FVII deficiency patients) and by stakeholder type (HCPs/investigators, patient advocacy groups, and public-market investors), with no current product sales channel.

Name

Hemab

Legal name

Hemab Therapeutics Holdings, Inc.

Website

https://hemab.com

Company type

Public

Founded year

2021

Operating status

Ipo

Headcount range

51–100 employees

Short description

Hemab is a clinical-stage biotech developing first-in-class subcutaneous prophylactic antibody therapies for underserved rare bleeding disorders — Glanzmann thrombasthenia, Von Willebrand Disease, and Factor VII deficiency — publicly listed on Nasdaq as COAG.

Ownership category

akta.pro rank

Product category

Rare Disease Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB)

akta.pro secondary industries

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI), Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

Keywords

• Rare disease biopharmaceuticals
• Bleeding disorder therapeutics
• Bispecific antibody development
• Monoclonal antibody therapies
• Subcutaneous prophylactic treatments

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pre-revenue clinical development: Hemab is a clinical-stage biotechnology company and is not yet generating product revenue. The company's lead assets (sutacimig for Glanzmann thrombasthenia/FVII deficiency, HMB-002 for VWD) are in Phase 1/2 to Phase 3 development. Following its May 2026 IPO, Hemab held approximately $460 million in pro-forma cash, intended to fund ongoing and upcoming registration studies rather than any current commercial sales.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels11 records

Core offering

Hemab is a clinical-stage biotechnology company developing first-in-class prophylactic antibody therapies for underserved inherited bleeding disorders. Its portfolio consists of two clinical-stage product candidates: Sutacimig (HMB-001), a bispecific antibody that targets endogenous FVIIa to activated platelets for subcutaneous prophylaxis in Glanzmann Thrombasthenia and Factor VII Deficiency, and HMB-002, a monovalent antibody that elevates endogenous VWF and FVIII levels for subcutaneous prophylaxis in Von Willebrand Disease. The company's modality-agnostic platform engineers antibodies that connect to the body's natural clotting proteins, stabilize them from premature breakdown, accumulate them to hemostatic levels, and direct them to sites of injury to drive localized coagulation.

Product overview

Hemab Therapeutics operates a single, focused clinical-stage biotechnology pipeline rather than a multi-product platform. Its portfolio is anchored by two bispecific/monovalent antibody product candidates developed as subcutaneous prophylactic treatments for underserved inherited bleeding disorders. The lead asset, Sutacimig (HMB-001), is a bispecific antibody targeting FVIIa to activated platelets and is in Phase 1/2 (NCT06211634, fully enrolled with long-term extension ongoing) for Glanzmann Thrombasthenia, with a pivotal Phase 3 study anticipated in H2 2026 following positive complete Phase 2 data presented at ASH 2025; a separate Phase 2 study in Congenital Factor VII Deficiency (NCT07347249) is actively enrolling. The second asset, HMB-002, is a monovalent antibody that elevates circulating VWF and FVIII levels and is being developed in the actively enrolling Phase 1/2 VELORA Pioneer trial (NCT06754852) for Von Willebrand Disease, supported by the prospective natural history VELORA Discover screening study (NCT06610201). Hemab's broader R&D approach is modality-agnostic and targets Factor VII deficiency, Von Willebrand Disease, Glanzmann Thrombasthenia, and additional coagulation disorders, with all clinical and scientific communications centralized in the Empirium news and presentations hub.

Differentiator

Problem solved

Functional benefit

Brands

• Sutacimig: Lead clinical-stage bispecific antibody product candidate (also designated HMB-001) being developed by Hemab for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.
• Empirium

Products and services

• Sutacimig (HMB-001) Sutacimig (HMB-001) is Hemab's lead clinical-stage product candidate, a first-in-class novel bispecific antibody that accumulates and targets endogenous FVIIa to activated platelets at sites of injury to enhance thrombin generation and fibrin formation. It is being developed as a subcutaneous prophylactic treatment for Glanzmann Thrombasthenia (Phase 1/2 NCT06211634, fully enrolled with long-term extension ongoing) and for Congenital Factor VII Deficiency (Phase 2 NCT07347249, actively enrolling single ascending dose cohorts).
• HMB-002 HMB-002 is Hemab's second clinical-stage product candidate, a first-in-class monovalent antibody designed to elevate circulating endogenous VWF and Factor VIII levels for subcutaneous prophylactic treatment of Von Willebrand Disease. It is currently being evaluated in the actively enrolling Phase 1/2 VELORA Pioneer trial (NCT06754852) and supported by the prospective VELORA Discover natural history screening study (NCT06610201).

Quantifiable outcome

• Positive complete Phase 2 data for sutacimig in Glanzmann thrombasthenia announced at ASH 2025, demonstrating significant reductions in bleeding events and safety, supporting advancement to a pivotal Phase 3 study
• +3 more outcomes

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alnylam Pharmaceuticals: Rare-disease biotech pioneering RNAi therapeutics. Hemab's Board Chair John Maraganore was Alnylam's founding CEO for nearly 20 years; CEO Sorensen led fitusiran development at Alnylam; COO Murthy, VP Amin, Director Vaishnaw, and Head of Biometrics He all came from Alnylam, creating deep talent and approach overlap in rare-disease drug development.
• argenx: Antibody platform biotech commercializing VYVGART for rare autoimmune diseases. Hemab's COO Anant Murthy was previously General Manager of EMEA at argenx and led the international launch of VYVGART, and the company shares a similar model of platform-driven antibody therapeutics for underserved indications with high unmet need.
• Genmab: Antibody platform company developing bispecific and next-generation antibody therapeutics. Multiple Hemab executives and directors (Bak-Thomsen, Jønsson, Goldenbæk, Poulsen) previously led antibody development, CMC, and analytics at Genmab, providing shared expertise in bispecific antibody design and regulatory-grade manufacturing.

Broad incumbents

• BioMarin Pharmaceutical: Established rare-disease biotech with a commercial hemophilia franchise (e.g., Roctavian for hemophilia A gene therapy). BioMarin represents a larger, commercially active rare-disease peer with overlapping indication space (bleeding disorders) but a wider therapeutic portfolio.
• Sanofi: Large pharmaceutical company with an established hemophilia and rare bleeding disorder franchise (Eloctate, Altuviiio, and Bioverativ legacy assets). Hemab's SVP CMC Cécile Bonvoisin previously led biologics manufacturing at Sanofi, and Sanofi operates as a broad incumbent in the same disease space Hemab targets.
• Takeda Pharmaceutical: Large pharmaceutical company that acquired Shire/Baxalta, inheriting a major hemophilia and bleeding-disorder franchise (Advate, Adynovate, Vonvendi). Hemab's VP Regulatory Erik Bjornson and Director Supply Chain Bernd Schaden both previously held senior roles across the Baxalta/Shire/Takeda hemophilia portfolio, and Takeda represents the dominant incumbent in the adjacent bleeding-disorder market.
• Novo Nordisk: Large pharmaceutical company with a global hemophilia franchise (NovoSeven, NovoEight, Refixia, Alhemo). Multiple Hemab scientific and clinical leaders (Østergaard, Laustsen, Mathy, Nagilla, Bak-Thomsen, Jensen, Jeppesen) and the Series A lead investor Novo Holdings connect Hemab's R&D approach to Novo Nordisk's hemophilia portfolio.
• Pfizer: Large pharmaceutical company with hemophilia assets including the recently approved Beqvez gene therapy for hemophilia B (acquired via Spark Therapeutics) and broader rare-disease franchise. Pfizer represents a major incumbent competing in adjacent bleeding-disorder therapeutic modalities (gene therapy vs. Hemab's antibody approach).

Emerging players

• uniQure: Clinical-stage gene therapy company developing etranacogene dezaparvovec for hemophilia B. uniQure is comparable to Hemab as a focused, late-clinical-stage biotech addressing rare inherited bleeding disorders but pursues a gene-therapy modality rather than antibody-based prophylaxis.
• Ascendis Pharma: Rare-disease biotech with TransCon technology platform and approved endocrine products. Multiple Hemab directors and VPs (Caroline Rasmussen, Anja Skands, Mette Ulbak) previously held senior nonclinical, drug-product, and regulatory roles at Ascendis, and the company represents a similarly sized rare-disease platform peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Hemab_Tx
• LinkedInlinkedin.com/company/hemabaps
• Instagraminstagram.com/hemab_therapeutics/?hl=en
• Facebookfacebook.com/HemabTherapeutics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemab